1. Muscle‐to‐fat ratio identifies functional impairments and cardiometabolic risk and predicts outcomes: biomarkers of sarcopenic obesity
- Author
-
Pei‐Chin Yu, Chia‐Chia Hsu, Wei‐Ju Lee, Chih‐Kuang Liang, Ming‐Yueh Chou, Ming‐Hsien Lin, Fei‐Yuan Hsiao, Li‐Ning Peng, and Liang‐Kung Chen
- Subjects
Male ,Sarcopenia ,Sarcopenic obesity ,Hand Strength ,Muscles ,QM1-695 ,Diseases of the musculoskeletal system ,Cardiovascular disease ,RC925-935 ,Adipose Tissue ,Cardiovascular Diseases ,Muscle‐to‐fat ratio ,Physiology (medical) ,Human anatomy ,Humans ,Falls ,Female ,Orthopedics and Sports Medicine ,Obesity ,Biomarkers ,Aged - Abstract
Background Sarcopenic obesity aims to capture the risk of functional decline and cardiometabolic diseases, but its operational definition and associated clinical outcomes remain unclear. Using data from the Longitudinal Aging Study of Taipei, this study explored the roles of the muscle‐to‐fat ratio (MFR) with different definitions and its associations with clinical characteristics, functional performance, cardiometabolic risk and outcomes. Methods (1) Appendicular muscle mass divided by total body fat mass (aMFR), (2) total body muscle mass divided by total body fat mass (tMFR) and (3) relative appendicular skeletal muscle mass (RASM) were measured. Each measurement was categorized by the sex‐specific lowest quintiles for all study participants. Clinical outcomes included all‐cause mortality and fracture. Results Data from 1060 community‐dwelling older adults (mean age: 71.0 ± 4.8 years) were retrieved for the study. Overall, 196 (34.2% male participants) participants had low RASM, but none was sarcopenic. Compared with those with high aMFR, participants with low aMFR were older (72 ± 5.6 vs. 70.7 ± 4.6 years, P = 0.005); used more medications (2.9 ± 3.3 vs. 2.1 ± 2.5, P = 0.002); had a higher body fat percentage (38 ± 4.8% vs. 28 ± 6.4%, P
- Published
- 2021